Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New RNA therapy aims to tame Out-of-Control immune system

NCT ID NCT07322718

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called RXIM002 for people with severe autoimmune diseases that haven't responded to standard therapies. The treatment uses a special RNA molecule to create immune cells that target and destroy faulty B cells, which are causing the disease. The main goals are to check if the treatment is safe and to see how long the modified cells stay in the body. About 27 adults aged 18 to 65 with conditions like lupus are being enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 27 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects voluntary agreement to provide written informed consent. * Aged 18 to 65 years, either sex. * Adequate organ function meeting screening criteria. * Positive test for cluster of differentiation antigen 19 (CD19). Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN): * Have been diagnosed with SLE or LN before screening. * Presence of anti-dsDNA, anti-histone, anti-chromatin, anti-Ro (anti-SS-A), anti-La (anti-SS-B), antinuclear antibody (ANA), or anti-Sm antibodies at screening. * Active disease at screening. * Fulfill relapsed/refractory SLE or LN conditions Lupus Nephritis (LN) : * Kidney biopsy result indicating LN * Evidence of LN disease activity Systemic Sclerosis (SSc): * Have been diagnosed with SSc before screening. * Antinuclear Antibody (ANA) positive at screening or prior to screening. AND, evidence of SSc disease activity. * Fulfill relapsed/refractory SSc conditions. Immune Thrombocytopenia (ITP): * Have been diagnosed with refractory ITP before screening. * Platelet count \<50×10⁹/L at screening. Idiopathic Inflammatory Myopathy (IIM): * Have been diagnosed with IIM before screening. * Presence of at least 1 myositis specific (MSA), associated antibody (MAA), or ANA at screening or prior to screening. * Evidence of IIM disease activity. * Fulfill relapsed/refractory IIM conditions. Membranous Nephropathy (MN): * Have been diagnosed with MN before screening. * Active MN patients meeting screening criteria. * Fulfill relapsed/refractory MN conditions. Autoimmune Hemolytic Anemia (AIHA): * Have been diagnosed with AIHA before screening. * Active AIHA patients meeting screening criteria. * Fulfill relapsed/refractory AIHA conditions. Exclusion Criteria: * Active infections such as hepatitis and tuberculosis. * Other autoimmune diseases. * Serious underlying diseases such as active malignancies, uncontrolled diabetes. * Female subjects who were pregnant, breastfeeding. * Any uncontrolled psychiatric disorders (e.g., schizophrenia, bipolar disorder, eating disorders, major depression or anxiety disorder), as declared by the participant or reported in the medical records.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune hemolytic anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ruijin Hospital

    RECRUITING

    Shanghai, Huangpu District, No. 197, Ruijin 2nd Road, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.